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Abstract
IMPORTANCE Behavioral disturbances are core features of frontotemporal dementia (FTD);
however, symptom progression across the course of disease is not well characterized in genetic FTD.
OBJECTIVE To investigate behavioral symptom frequency and severity and their evolution and
progression in different forms of genetic FTD.
DESIGN, SETTING, AND PARTICIPANTS This longitudinal cohort study, the international Genetic
FTD Initiative (GENFI), was conducted from January 30, 2012, to May 31, 2019, at 23 multicenter
specialist tertiary FTD research clinics in the United Kingdom, the Netherlands, Belgium, France,
Spain, Portugal, Italy, Germany, Sweden, Finland, and Canada. Participants included a consecutive
sample of 232 symptomatic FTD gene variation carriers comprising 115 with variations in C9orf72, 78
in GRN, and 39 in MAPT. A total of 101 carriers had at least 1 follow-up evaluation (for a total of 400
assessments). Gene variations were included only if considered pathogenetic.
MAIN OUTCOMES AND MEASURES Behavioral and neuropsychiatric symptoms were assessed
across disease duration and evaluated from symptom onset. Hierarchical generalized linear mixed
models were used to model behavioral and neuropsychiatric measures as a function of disease
duration and variation.
RESULTS Of 232 patients with FTD, 115 (49.6%) had a C9orf72 expansion (median [interquartile
range (IQR)] age at evaluation, 64.3 [57.5-69.7] years; 72 men [62.6%]; 115 White patients [100%]),
78 (33.6%) had a GRN variant (median [IQR] age, 63.4 [58.3-68.8] years; 40 women [51.3%]; 77
White patients [98.7%]), and 39 (16.8%) had a MAPT variant (median [IQR] age, 56.3 [49.9-62.4]
years; 25 men [64.1%]; 37 White patients [94.9%]). All core behavioral symptoms, including
disinhibition, apathy, loss of empathy, perseverative behavior, and hyperorality, were highly
expressed in all gene variant carriers (>50% patients), with apathy being one of the most common
and severe symptoms throughout the disease course (51.7%-100% of patients). Patients with MAPT
variants showed the highest frequency and severity of most behavioral symptoms, particularly
disinhibition (79.3%-100% of patients) and compulsive behavior (64.3%-100% of patients),
compared with C9orf72 carriers (51.7%-95.8% of patients with disinhibition and 34.5%-75.0% with
compulsive behavior) and GRN carriers (38.2%-100% with disinhibition and 20.6%-100% with
compulsive behavior). Alongside behavioral symptoms, neuropsychiatric symptoms were very
frequently reported in patients with genetic FTD: anxiety and depression were most common in GRN
carriers (23.8%-100% of patients) and MAPT carriers (26.1%-77.8% of patients); hallucinations,
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Abstract (continued)
particularly auditory and visual, were most common in C9orf72 carriers (10.3%-54.5% of patients).
Most behavioral and neuropsychiatric symptoms increased in the early-intermediate phases and
plateaued in the late stages of disease, except for depression, which steadily declined in C9orf72
carriers, and depression and anxiety, which surged only in the late stages in GRN carriers.
CONCLUSIONS AND RELEVANCE This cohort study suggests that behavioral and neuropsychiatric
disturbances differ between the common FTD gene variants and have different trajectories
throughout the course of disease. These findings have crucial implications for counseling patients
and caregivers and for the design of disease-modifying treatment trials in genetic FTD.
JAMA Network Open. 2021;4(1):e2030194. doi:10.1001/jamanetworkopen.2020.30194
Introduction
Frontotemporal dementia (FTD) encompasses a heterogeneous group of neurodegenerative
disorders with a wide range of clinical, genetic, and neuropathological features.1 Approximately
one-third of patients with FTD have an autosomal dominant family history,2 with variations of 3 main
genes, microtubule-associated protein tau (MAPT), granulin (GRN), and chromosome 9 open reading
frame 72 (C9orf72), together accounting for 10% to 20% of all FTD and 70% of all genetic FTD
cases.3,4 Behavioral and personality changes are among the most prominent symptoms in FTD,
particularly in the behavioral variant FTD,5 but are also seen in the primary progressive aphasias,6 in
which behavioral symptoms are frequently associated with speech and language deficits.7-10
Irrespective of the particular presenting syndrome, these disturbances progress over time, with
symptoms changing over the course of the disease.11-13 Several studies have investigated the
development of behavioral disturbances in sporadic FTD,14-19 with a recent study showing that the
progression and severity of behavioral symptoms may change during the course of the disease.20
Negative symptoms, such as apathy and loss of empathy, steadily increase throughout the course of
disease, whereas positive symptoms, such as disinhibition and perseverative behavior, tend to
worsen until the intermediate stages and then decrease in severity in the more advanced phases.20
However, this progression has not been systematically addressed within and across the
symptomatic phases of genetic FTD, and it is currently unclear how behavioral and neuropsychiatric
symptoms change during the course of the disease and whether different gene variants have distinct
patterns of symptom progression. This question has crucial implications for counseling patients and
caregivers and should be pivotal when designing clinical outcomes and monitoring measures for
disease-modifying treatment trials for each specific gene. The aim of the present study was to
investigate and characterize the frequency, evolution, and progression of behavioral and
neuropsychiatric symptoms in a large cohort of patients with genetic FTD in the international Genetic
FTD Initiative (GENFI),21 hypothesizing that the nature and severity of behavioral disturbances may
follow different trajectories depending on the gene variant.
Methods
Participants
In this longitudinal cohort study, patients were recruited from 23 multicenter specialist tertiary FTD
research clinics in the United Kingdom, the Netherlands, Belgium, France, Spain, Portugal, Italy,
Germany, Sweden, Finland, and Canada. From the GENFI study21 data freeze 5 (from January 30,
2012, to May 31, 2019), a consecutive sample of 232 symptomatic participants were included,
comprising 115 with gene variations in C9orf72, 78 in GRN, and 39 in MAPT. Gene variants were
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included only if considered pathogenetic (full inclusion and exclusion criteria are reported in the
eMethods and eTables 1 and 2 in the Supplement).
Patients were considered symptomatic when the assessing clinician felt that the patient had
evidence of progressive cognitive or behavioral change. All participants underwent genetic testing to
determine whether they were a carrier or noncarrier. All participants underwent the GENFI
standardized assessment.21 During the first visit, demographic information of all participants was
collected, as well as information regarding clinical background (neuropsychiatric features, family and
medical history, medication, and onset symptoms).
Local ethics committees approved the study at each site, and all participants provided written
informed consent. The study was conducted according to the Declaration of Helsinki22 and followed
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline.
Clinical Evaluation
Participants underwent a clinical and cognitive assessment to evaluate their symptomatic status and
cognitive performance at baseline and then at follow-up (232 with baseline assessment, 101 with at
least 2 evaluations, 35 with at least 3 evaluations, 15 with at least 4 evaluations, 8 with at least 5
evaluations, 7 with at least 6 evaluations, and 3 with 7 evaluations), for a total of 400 evaluations
(eTable 3 in the Supplement).
In all patients, both behavioral and neuropsychiatric symptoms were assessed, and severity was
rated on a 5-point scale (0 = absent, 0.5 = questionable or very mild, 1 = mild, 2 = moderate, and
3 = severe). Behavioral symptoms included disinhibition, apathy, loss of sympathy or empathy,
compulsive or ritualistic behavior, hyperorality, and dietary changes. Neuropsychiatric symptoms
included visual, auditory, and tactile hallucinations; delusions; depression; and anxiety. We measured
functional status using the Frontotemporal Dementia Rating Scale, which has a very high interrater
variability (intraclass correlation coefficient of 0.994).17
Statistical Analysis
Baseline demographic and clinical variables were compared across groups using the Kruskal-Wallis H
test or Fisher test, as appropriate.
Hierarchical generalized linear mixed models were used to model behavioral and
neuropsychiatric measures as a function of disease duration, evaluated in years from symptom onset,
and gene variation (C9orf72, GRN, or MAPT). A gamma regression was applied owing to the skewed
distribution of behavioral and neuropsychiatric measures.23 As previously reported, possible
nonlinear changes, such as quadratic and cubic relations, could be expected over time for each
measure.20,21 Accordingly, possible 2-factor and 3-factor interaction terms along with second- and
third-order terms were examined to reach a final model that fit the data well (eTable 4 in the
Supplement). A penalized likelihood method (bayesian information criteron) was also considered to
evaluate the model fit.24 Considering that some participants were recruited from the same family,
the family membership was included in the model as a random effect, as it was expected that
members from the same family might have covariance in symptom intensity and progression due to
a shared genetic and environmental background. A random-effects model was used to estimate the
variance in the effect of a variable between different clusters in the data, and this estimation allowed
for correlation in the outcome between members of the same cluster.25,26
We performed Satterthwaite approximations with robust covariances for each model to assess
whether the mean value of the measure differed between gene variants. We predicted average
values from the mixed-effects model for each group and differences between gene variants at
different time points (0-4 years, 4-8 years, and 8-12 years of disease duration, evaluated from
symptom onset). We applied Bonferroni adjustments for multiple comparisons, with an adjusted α
level of .0028 (18 comparisons per symptom). All time points were arbitrarily defined in order to
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distribute an equal number of patients in the 3 categories, roughly corresponding to an early,
intermediate, and late phase.
Statistical significance was assumed at P < .05, and P values were 2-sided. Data analyses were
carried out using SPSS, version 25.0 (IBM Corp) and GraphPad Prism, version 8.0 (GraphPad
Software).
Results
Of 232 patients with FTD, 115 (49.6%) had a C9orf72 expansion (median [interquartile range (IQR)]
age at evaluation, 64.3 [57.5-69.7] years; 72 men [62.6%]; 115 White patients [100%]), 78 (33.6%)
had a GRN variant (median [IQR] age, 63.4 [58.3-68.8] years; 40 women [51.3%]; 77 White patients
[98.7%]), and 39 (16.8%) had a MAPT variant (median [IQR] age, 56.3 [49.9-62.4] years; 25 men
[64.1%]; 37 White patients [94.9%]). Demographic characteristics of the patients included are
reported in Table 1. There were significant differences in age at symptom onset between groups,
with GRN (median [IQR] age, 60.0 [55.0-66.0] years; P < .001) and C9orf72 carriers (median [IQR]
age, 59.0 [53.0-65.0] years) being significantly older than MAPT carriers (median [IQR] age, 52.0
[45.0-56.0] years). Patients with variations in MAPT (median [IQR] duration, 3.3 [1.7-7.6] years) and
C9orf72 (median [IQR] duration, 3.9 [2.2-5.9] years) expansions had a longer disease duration at
baseline compared with GRN carriers (median [IQR] duration, 2.4 [1.4-3.5] years; P = .001). No
differences were observed between groups in terms of sex, years of education, or disease severity
evaluated with the Frontotemporal Dementia Rating Scale. Disease severity was not significantly
different between sexes, both in the whole cohort of patients and within specific genetic groups.
Frequency of Behavioral and Neuropsychiatric Symptoms
The frequencies of behavioral and neuropsychiatric symptoms are reported in Figure 1 for each gene
variant, expressed as percentage of patients reporting that particular symptom out of the total
number of patients with that specific disease duration, evaluated from symptom onset.
C9orf72
We observed a high frequency (27.6%-95.8% of patients) of all behavioral symptoms in C9orf72
carriers, particularly in the intermediate and late stages of disease (74.3%-95.8% of patients with
disinhibition, 82.4%-87.5% with apathy, 81.1%-95.8% with loss of empathy, 67.6%-75.0% with
compulsive behavior, 71.6%-87.5% with hyperorality), with only slightly lower frequencies for
compulsive behavior and hyperorality in the first 4 years of the disease (34.5%-53.2% of patients
with compulsive behavior, 27.6%-58.5% with hyperorality). Depression and anxiety were present in
approximately one-third of patients in the early stages (37.2%-44.0% of patients with depression,
27.6%-43.6% with anxiety), whereas in the intermediate stages, all neuropsychiatric symptoms were
Table 1. Baseline Demographic and Clinical Characteristics of Patients With FTD
Characteristic
Median (IQR)a
C9orf72 (n = 115) GRN (n = 78) MAPT (n = 39)
Female sex, No. (%) 43 (37.4) 40 (51.3) 14 (35.9)
Ethnicity, No. (%)
White 115 (100) 77 (98.7) 37 (94.9)
African 0 0 2 (5.1)
Indian 0 1 (1.3) 0
Education, y 13.0 (11.0-15.0) 12.0 (8.0-15.0) 13.0 (11.0-16.0)
Age at symptom onset, y 59.0 (53.0-65.0)b 60.0 (55.0-66.0) 52.0 (45.0-56.0)c,d
Disease duration, y 3.9 (2.2-5.9)c 2.4 (1.4-3.5)b,d 3.3 (1.7-7.6)d
Person-years of follow-up 93.8 47.0 47.9
Frontotemporal Dementia Rating Scale, % 38.0 (17.0-60.0) 46.5 (22.8-68.1) 40.0 (25.0-57.0)
Abbreviations: C9orf72, chromosome 9 open reading
frame 72; FTD, frontotemporal dementia; GRN,
granulin; IQR, interquartile range; MAPT, microtubule-
associated protein tau.
a Values are listed as median (IQR) unless otherwise
specified.
b P < .05 vs MAPT pairwise comparisons after
significant interaction at the Kruskal-Wallis H test or
at the Fisher exact test, after adjustment for multiple
comparisons.
c P < .05 vs GRN.
d P < .05 vs C9orf72.
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Figure 1. Frequency of Behavioral and Neuropsychiatric Symptoms in
A, C9orf72 Expansion; B, GRN; and C, MAPT Carriers
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0.0% 2.9% 13.8% 21.7% 23.8% 33.3% 33.3%
42.9% 35.3% 27.6% 26.1% 38.1% 50.0% 33.3%
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C9orf72 indicates chromosome 9 open reading frame 72; GRN, granulin; MAPT,
microtubule-associated protein tau.
a P < .05 vs GRN.
b P < .05 vs C9orf72.
c P < .05 vs MAPT pairwise comparisons after significant interaction at the
Fisher exact test, after adjustment for multiple comparisons.
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evenly distributed (33.8%-41.7% of patients with hallucinations, 37.8%-38.9% with delusions,
27.0%-27.8% with depression, 41.9%-55.6% with anxiety). By the late stages, anxiety and
hallucinations predominated (50.0% of patients with anxiety, 41.7%-54.5% with hallucinations)
(Figure 1A).
GRN
Apathy, loss of empathy, and hyperorality were the most frequent symptoms, already present in
more than 50% of patients during the early stages (67.6%-84.1% of patients with apathy, 58.8%-
68.3% with loss of empathy, 55.9%-65.1% with hyperorality). In the late stages, all behavioral
symptoms were seen in nearly all patients (100% of patients with disinhibition, 100% with apathy,
66.7%-80.0% with loss of empathy, 80.0%-100% with compulsive behavior, 80.0%-100% with
hyperorality). Depression and anxiety were the most frequent neuropsychiatric symptoms,
particularly in the early (42.9%-47.1% of patients with depression, 44.1%-55.6% with anxiety) and
late (60.0%-100% of patients with depression, 40.0%-100% with anxiety) phases, when compared
with hallucinations (0.0%-32.3% of patients) and delusions (0.0%-40.0% of patients) (Figure 1B).
MAPT
The frequency of behavioral disturbances was extremely high in patients with MAPT gene variations,
with more than 60% of patients reporting all symptoms in the early disease stages (79.3%-85.7%
of patients with disinhibition, 75.9%-78.6% with apathy, 64.3%-69.0% with loss of empathy, 64.3%-
79.3% with compulsive behavior), except for hyperorality (42.9%-55.2% of patients). By contrast,
hallucinations (0.0%-13.0% of patients) and delusions (0.0%-33.3% of patients) were not at all
frequent during the course of the disease. Depression and anxiety were moderately represented
during the entire course of the disease (26.1%-50.0% of patients with depression, 31.0%-77.8% with
anxiety), with the latter increasing in the final stages (66.7%-77.8% of patients) (Figure 1C).
Longitudinal Behavioral Changes
Estimates of longitudinal changes in behavioral symptoms are reported in Figure 2A, 2B, and 2C for
each gene variant, expressed as average severity for each symptom on a 5-point scale (0, 0.5, 1, 2,
and 3) as a function of disease duration and evaluated from symptom onset.
C9orf72
In the early phases of disease (0-4 years), we observed a significant predominance of apathy (mean
severity score: 1.22 [95% CI, 1.05-1.38] points) compared with other behavioral symptoms in C9orf72
carriers, which tended to plateau in the intermediate (mean severity score at 4-8 years: 1.67 [95%
CI, 1.52-1.82] points) and late (mean severity score at 8-12 years: 1.62 [95% CI, 1.47-1.78] points)
stages, when loss of empathy or sympathy became the predominant behavioral symptom (mean
severity score at 4-8 years: 1.58 [95% CI, 1.45-1.70] points; at 8-12 years: 1.92 [95% CI, 1.79-2.04]
points) (Table 2 and Figure 2A). All other behavioral symptoms, such as disinhibition, compulsive
behavior, and hyperorality, had similar trajectories, being less severe and steadily increasing in the
early phases and then slowing down in the intermediate-late phases.
GRN
Similar to C9orf72, GRN carriers had apathy as the predominant symptom (mean severity score at 1-4
years: 1.34 [95% CI, 1.19-1.49] points), which increased into intermediate-late stages (mean severity
score at 4-8 years: 1.69 [95% CI, 1.37-2.01] points; at 8-12 years: 1.93 [95% CI, 1.57-2.29] points). Loss
of empathy (mean severity score: 0.93 [95% CI, 0.82-1.04] points) and hyperorality (mean severity
score: 0.95 [95% CI, 0.82-1.09] points) were the next most severe behavioral symptoms in the early
disease stages, with loss of empathy steadily increasing over the course of the disease (mean severity
score at 4-8 years: 1.29 [95% CI, 1.02-1.55] points; at 8-12 years: 1.81 [95% CI, 1.23-2.39] points),
whereas hyperorality remained stable (mean severity score at 4-8 years: 1.01 [95% CI, 0.79-1.22]
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points; at 8-12 years: 1.36 [95% CI, 0.87-1.85] points). Compulsive behavior and disinhibition were
less pronounced in the early and intermediate stages, and increased in the late phases (mean severity
score at 0-4 years: compulsive behavior, 0.48 [95% CI, 0.38-0.58] points; disinhibition, 0.61 [95%
CI, 0.49-0.74] points; at 4-8 years: compulsive behavior, 0.75 [95% CI, 0.57-0.93] points;
disinhibition, 0.62 [95% CI, 0.40-0.83] points; at 8-12 years: compulsive behavior, 1.43 [95% CI,
0.67-2.19] points; disinhibition, 1.07 [95% CI, 0.59-1.55] points) (Table 2 and Figure 2B).
MAPT
In MAPT carriers, disinhibition was the predominant symptom in the early phase (mean severity
score: 1.01 [95% CI, 0.83-1.19] points), as compared with C9orf72 (mean severity score: 0.67 [95% CI,
0.54-0.80] points) and GRN carriers (mean severity score: 0.61 [95% CI, 0.49-0.74] points).
Compulsive behavior was also significantly increased in the early phase (mean severity score: 0.80
[95% CI, 0.67-0.93] points) compared with the other 2 variations (mean severity score: C9orf72,
0.62 [95% CI, 0.49-0.74] points; GRN, 0.48 [95% CI, 0.38-0.58] points). In the intermediate and late
phases, all behavioral symptoms progressively worsened following similar trajectories, and
Figure 2. Predicted Behavioral (A, C9orf72 carriers; B, GRN carriers; C, MAPT carriers) and Neuropsychiatric Symptom (D, C9orf72 carriers; E, GRN carriers; F, MAPT carriers)
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C9orf72 indicates chromosome 9 open reading frame 72; GRN, granulin; MAPT, microtubule-associated protein tau.
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hyperorality was significantly increased in the late phase (mean severity score: 2.09 [95% CI, 1.87-
2.30] points) compared with C9orf72 (mean severity score: 1.57 [95% CI, 1.35-1.79] points) and GRN
(mean severity score: 1.36 [95% CI, 0.87-1.85] points) carriers (Table 2 and Figure 2C).
Longitudinal Changes in Neuropsychiatric Symptoms
Estimates of longitudinal changes in neuropsychiatric symptoms are reported in Figure 2D, 2E, 2F,
and Table 2 for each variation, expressed as mean severity for each symptom on a 5-point scale (0,
0.5, 1, 2, and 3) as a function of disease duration, evaluated from symptom onset (significant pairwise
comparisons are reported in eFigure 1 in the Supplement as Circos plots.27)
C9orf72
In the early phase of disease, depression was the predominant symptom in C9orf72 and tended to
steadily decline in the intermediate and late phases (mean severity score at 0-4 years: 0.53 [95% CI,
0.45-0.61] points; at 4-8 years: 0.32 [95% CI, 0.25-0.38] points; at 8-12 years: 0.38 [95% CI, 0.27-
0.49] points), when hallucinations tended to prevail over other neuropsychiatric symptoms (mean
severity score at 4-8 years: 0.61 [95% CI, 0.41-0.82] points; at 8-12 years: 0.75 [95% CI, 0.41-1.10]
points) (Table 2 and Figure 2D). All other symptoms tended to plateau in the late stages of disease,
being less severe than hallucinations. Auditory and visual hallucinations steadily increased during the
Table 2. Estimates of Behavioral and Neuropsychiatric Symptoms’ Severity in Patients With FTD
Symptom
Mean (95% CI) severity score
0-4 y From symptom onset 4-8 y From symptom onset 8-12 y From symptom onset
C9orf72
Disinhibition 0.67 (0.54-0.80)a,b,c 1.20 (1.05-1.35)b,d,e 1.37 (1.22-1.52)a,d
Apathy 1.22 (1.05-1.38)a,b 1.67 (1.52-1.82)d 1.62 (1.47-1.78)d
Loss of empathy 0.94 (0.81-1.07)a,b 1.58 (1.45-1.70)b,d 1.92 (1.79-2.04)a,d
Compulsive behavior 0.62 (0.49-0.74)a,b 1.16 (1.01-1.30)d 1.28 (1.09-1.46)d
Hyperorality 0.54 (0.43-0.65)a,b,e 1.26 (1.11-1.40)d 1.57 (1.35-1.79)d
Hallucinations 0.41 (0.25-0.57)e 0.61 (0.41-0.82) 0.75 (0.41-1.10)c
Delusions 0.22 (0.14-0.29)a 0.52 (0.39-0.66)c,d,e 0.50 (0.32-0.68)
Depression 0.53 (0.45-0.61)a 0.32 (0.25-0.38)d 0.38 (0.27-0.49)
Anxiety 0.47 (0.39-0.56)b 0.51 (0.45-0.57)b 0.65 (0.51-0.80)a,d
GRN
Disinhibition 0.61 (0.49-0.74)c 0.62 (0.40-0.83) 1.07 (0.59-1.55)
Apathy 1.34 (1.19-1.49)c 1.69 (1.37-2.01) 1.93 (1.57-2.29)
Loss of empathy 0.93 (0.82-1.04)a 1.29 (1.02-1.55)d 1.81 (1.23-2.39)a,d
Compulsive behavior 0.48 (0.38-0.58)a,c 0.75 (0.57-0.93)d 1.43 (0.67-2.19)
Hyperorality 0.95 (0.82-1.09)f 1.01 (0.79-1.22) 1.36 (0.87-1.85)
Hallucinations 0.14 (0.06-0.21)a,f 0.37 (0.20-0.55)c,d 0.18 (0.00-0.40)
Delusions 0.12 (0.07-0.17)c,f 0.17 (0.05-0.29)f 0.11 (0.00-0.23)
Depression 0.48 (0.42-0.55) 0.27 (0.17-0.37) 0.78 (0.11-1.46)
Anxiety 0.51 (0.43-0.58) 0.39 (0.29-0.50) 0.95 (0.05-1.84)
MAPT
Disinhibition 1.01 (0.83-1.19)e,f 1.26 (1.00-1.52)e 1.86 (1.58-2.15)e,f
Apathy 0.92 (0.75-1.09)b,e 1.35 (1.04-1.66)b 2.07 (1.93-2.22)a,d
Loss of empathy 0.71 (0.55-0.88)a,b 1.37 (0.97-1.76)d 1.82 (1.37-2.27)d
Compulsive behavior 0.80 (0.67-0.93)b,e 1.39 (1.09-1.69)b 1.69 (1.44-1.94)a,d
Hyperorality 0.55 (0.42-0.68)a,b 1.36 (1.07-1.65)b,d 2.09 (1.87-2.30)a,d
Hallucinations 0.02 (0.00-0.04)e,f 0.06 (0.00-0.12)e 0.06 (0.00-0.13)f
Delusions 0.06 (0.00-0.14) 0.25 (0.08-0.43)f 0.23 (0.14-0.32)
Depression 0.34 (0.24-0.44) 0.31 (0.17-0.46)b 0.61 (0.47-0.76)a
Anxiety 0.38 (0.28-0.48)b 0.58 (0.42-0.74)b 0.97 (0.88-1.05)a,d
Abbreviations: C9orf72, chromosome 9 open reading
frame 72; FTD, frontotemporal dementia; GRN,
granulin; MAPT, microtubule-associated protein tau.
a P < .05 vs 4-8 years.
b P < .05 vs 8-12 years.
c P < .05 vs MAPT.
d P < .05 vs 0-4 years.
e P < .05 vs GRN.
f P < .05 vs C9orf72; pairwise contrasts after
adjustment for multiple comparisons.
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course of the disease (mean severity score at 0-4 years: auditory hallucinations, 0.22 [95% CI, 0.14-
0.31] points; visual hallucinations, 0.21 [95% CI, 0.14-0.27] points; at 4-8 years: auditory
hallucinations, 0.23 [95% CI, 0.14-0.31] points; visual hallucinations, 0.24 [95% CI, 0.17-0.30] points;
at 8-12 years: auditory hallucinations, 0.23 [95% CI, 0.14-0.31] points; visual hallucinations, 0.31
[95% CI, 0.22-0.39] points), whereas tactile hallucinations were not frequently reported (mean
severity score at 0-4 years: 0.04 [95% CI, 0.01-0.2] points; at 4-8 years: 0.03 [95% CI, 0.01-0.15]
points; at 8-12 years: 0.02 [95% CI, 0.01-0.18] points) (eFigure 2A in the Supplement).
GRN
Anxiety and depression significantly increased in the early stages of disease, gradually decreasing in
the intermediate stages and subsequently increasing again in the late stages (mean severity score at
0-4 years: anxiety, 0.51 [95% CI, 0.43-0.58] points; depression, 0.48 [95% CI, 0.42-0.55] points; at
4-8 years: anxiety, 0.39 [95% CI, 0.29-0.50] points; depression, 0.27 [95% CI, 0.17-0.37] points; at
8-12 years: anxiety, 0.95 [95% CI, 0.05-1.84] points; depression, 0.78 [95% CI, 0.11-1.46] points).
Delusions and, to a lesser extent, hallucinations were less prominent when compared with C9orf72
carriers, particularly in the early and late stages (mean severity score for delusions at 0-4 years: 0.12
[95% CI, 0.07-0.17] points in GRN carriers vs 0.22 [95% CI, 0.14-0.29] points in C9orf72; at 8-12 years:
0.11 [95% CI, 0.00-0.23] points in GRN carriers vs 0.50 [95% CI, 0.32-0.68] points in C9orf72
carriers) (Table 2 and Figure 2E). Visual hallucinations were the most severe type of hallucinations
across the course of the disease but were less severe than in C9orf72 carriers (mean severity score at
0-4 years: 0.09 [95% CI, 0.01-0.17] points; at 4-8 years: 0.19 [95% CI, 0.12-0.23] points; at 8-12
years: 0.20 [95% CI, 0.09-0.29] points) (eFigure 2B in the Supplement).
MAPT
As with GRN carriers, anxiety and depression were preponderant in the early phases and less severe
than in other gene variant groups, with anxiety steadily increasing during the course of the disease
(mean severity score at 0-4 years: 0.38 [95% CI, 0.28-0.48] points; at 4-8 years: 0.58 [95% CI, 0.42-
0.74] points; at 8-12 years: 0.97 [95% CI, 0.88-1.05] points), whereas depression increased only in
the later stages (mean severity score at 4-8 years: 0.31 [95% CI, 0.17-0.46] points; at 8-12 years: 0.61
[95% CI, 0.47-0.76] points). Delusions, and particularly hallucinations, were significantly less
frequent than in C9orf72 and GRN carriers (mean severity score for hallucinations at 0-4 years: 0.02
[95% CI, 0.00-0.04] points in MAPT carriers vs 0.14 [95% CI, 0.06-0.21] points in GRN carriers and
0.41 [95% CI, 0.25-0.57] points in C9orf72 carriers) (Table 2 and Figure 2F). In terms of the nature
of hallucinations, visual hallucinations accounted for the majority of this symptom (mean severity
score at 0-4 years: 0.02 [95% CI, 0.00-0.16] points; at 4-8 years: 0.05 [95% CI, 0.01-0.17] points; at
8-12 years: 0.06 [95% CI, 0.01-0.18] points) (eFigure 2C in the Supplement).
Discussion
Behavioral and neuropsychiatric symptoms occur frequently over the course of many
neurodegenerative disorders, but they are a core feature in FTD.5,15 A number of studies have
focused on the progression of behavioral disturbances in the symptomatic phase of sporadic FTD and
some in the presymptomatic phases of genetic FTD.14-21,28-32 However, to our knowledge, studies
are lacking in the frequency and evolution of these symptoms during the symptomatic phases of
monogenetic FTD. Furthermore, it has been unclear how different gene variations influence the
nature and progression of these very important symptoms, which have relevant consequences for
caregiver burden and quality of life.33
In the present study, we aimed to describe the relationship between the frequency and severity
of behavioral and neuropsychiatric symptoms and disease progression in each of the main genetic
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variants associated with FTD, namely C9orf72, GRN, and MAPT. We observed in a large cohort of well-
defined patients from the international GENFI study that frequencies and severity of behavioral
symptoms may overlap and also differ significantly between gene variants.
Results suggest that behavioral symptoms, such as disinhibition, apathy, loss of empathy,
perseverative and compulsive behavior, and hyperorality—the core symptoms of behavioral variant
FTD—were expressed in all FTD pathogenic variations, with apathy being one of the most severe
symptoms. Patients with the MAPT gene variant showed the highest frequency and severity of most
core behavioral symptoms when compared with C9orf72 and GRN carriers. However, alongside
behavioral symptoms, results suggest that neuropsychiatric symptoms were also frequently
reported in patients with genetic FTD. These manifestations, which are currently not defined as part
of the FTD core symptoms, should be sought during evaluation.
Neuropsychiatric symptoms were particularly highly expressed in C9orf72 carriers when
compared with the other gene variations. Results suggest that anxiety predominated in the early
phases of disease both in frequency and in severity, whereas hallucinations were more severe than
any other symptom in the intermediate and late phases. In GRN carriers, depression and anxiety were
predominant in both early and late phases of disease, whereas hallucinations and delusions were not
common. Patients with the MAPT gene variants were highly affected by anxiety, whereas
hallucinations and delusions were virtually absent.
Results suggest that hallucinations in different modalities were independently expressed in the
different gene variants and should be sought because they could be highly suggestive of a particular
genetic variation. In fact, C9orf72 carriers were characterized by both auditory and visual
hallucinations,34 with the former being more severe in the early-intermediate stages, whereas GRN
carriers experienced mostly visual hallucinations. As reported previously, hallucinations were,
however, not a distinctive feature of MAPT carriers.
The different behavioral and neuropsychiatric profiles largely reflected the discrete patterns of
atrophy observed in each genetic variant.32 C9orf72 and GRN carriers showed fewer differences in
frequencies and trajectories of behavioral and neuropsychiatric symptoms between them when
compared with MAPT carriers, possibly owing to their common underlying TAR DNA-binding protein
43 (TDP-43) proteinopathy, as opposed to tau pathology.35 Parallels between C9orf72 and GRN
carriers have also recently emerged regarding early cognitive symptoms,31 serum neurofilament light
measures,36 and age at symptom onset and death,37 compared with MAPT carriers. This similarity
could have crucial implications, because the direct comparison of symptoms among gene variant
groups may be important in the consideration of basket-design clinical trials where, for example,
patients with TDP-43 pathology arising from different gene variants (C9orf72 and GRN) may be
grouped together.31
These findings have important clinical implications. Knowledge of the pattern and prevalence
of behavioral and neuropsychiatric symptoms over the course of the disease is particularly relevant
for counseling patients and caregivers and for the evaluation of outcomes in FTD therapeutic trial
designs. Behavioral disturbances evolve differently according to the particular gene variant, with
relatively specific trajectories for each specific symptom. Knowing how symptoms evolve over the
course of the disease could help the clinician and the caregiver in decisions regarding future
management and therapeutic approaches.
Limitations
We acknowledge that this study has some limitations. First, the number of assessments was more
limited in advanced disease stages, possibly leading to some estimation errors. This limitation is in
common with other observational studies and is almost inevitable owing to the high rate of
institutionalization. Second, we cannot exclude possible effects of central nervous system–active
drugs used differently in each genetic group. Furthermore, the present work did not cover all of the
symptoms encountered during the course of the disease, as, for example, those reported in the
Frontal Behavioral Inventory,38,39 such as restlessness, irritability, and aggression, as well as those
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related to aphasia and comprehension deficits. Nevertheless, we evaluated the core symptoms that
define the criteria for behavioral variant FTD and that are virtually always encountered during the
disease. Considering the wide variability of symptoms in patients with genetic FTD, even within
individuals with the same gene variation in the same family, generalization of these results to single
patients could be misleading. The current analysis does, however, represent one of the largest and
best characterized studies in monogenic FTD to our knowledge. Further studies should assess the
actual correspondence between these models and the observed symptoms during the natural
history of the disease.
Conclusions
In conclusion, the results of this cohort study suggest that behavioral and neuropsychiatric
disturbances differ between the common FTD gene variations and have different trajectories
through the course of the disease. This finding has crucial implications for counseling patients and
caregivers and is very important for the design of disease-modifying treatment trials in genetic FTD.
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